Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
NCT ID: NCT06829472
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
120 participants
INTERVENTIONAL
2023-12-01
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT05991908
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease
NCT04269811
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT05674539
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS
NCT06247917
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
NCT05436561
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MBF100
Patients receive condoning regimen with melphalan (100mg/m2) with busulfan and fludarabine.
melphalan
conditioning regimen with melphalan, busulfan and fludarabine
MBF140
Patients receive condoning regimen with melphalan (140mg/m2) with busulfan and fludarabine.
melphalan
conditioning regimen with melphalan, busulfan and fludarabine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
melphalan
conditioning regimen with melphalan, busulfan and fludarabine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with MDS with bone marrow blast \>5% but remain less than 20% before transplantation
* Donor available: HLA matched sibling donor, 9\~10/10 matched unrelated donor or haplo-identical donor
* Inform consent provided
Exclusion Criteria
* Patients with abnormal liver, renal and cardiac function
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Clinical Research Center
UNKNOWN
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiong HU
Deputy director, Department of Hematology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
chun Wang
Role: STUDY_DIRECTOR
Go Broad Health Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rui Jin Hospital
Shanghai, Shanghai Municipality, China
Zhaxin Hospital, Go Broad Health Care
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MBF-RJH-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.